Skip to content

Autologous Bronchial Basal Cells Transplantation for Treatment of CRD Including COPD, BE and PF

Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Respiratory Disease (CRD) Including Chronic Obstructive Pulmonary Disease (COPD), Bronchiectasis (BE) and Pulmonary Fibrosis (PF)

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03153800
Enrollment
30
Registered
2017-05-15
Start date
2017-04-05
Completion date
2021-10-04
Last updated
2019-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Respiratory Disease

Brief summary

Chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), bronchiectasis (BE) or pulmonary fibrosis (PF) are usually not curable with damaged pulmonary structure and function. Bronchial basal cells are proved to regenerate bronchus and alveoli to repair the pulmonary injuries. In this study, we intend to perform an open, single-armed phase I clinical trial by transplantation of autologous bronchial basal cells on patients suffered from COPD, BE or PF. During the treatment, autologous bronchial basal cells, which were isolated from fiberoptic bronchoscopy and expanded in vitro, will be injected directly into lesions by fiberoptic bronchoscopy after careful characterization. In the following 6 months, the safety and efficacy of the treatment will be monitored by measuring the key clinical indicators.

Interventions

Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.

Sponsors

The First Affiliated Hospital of Soochow University
CollaboratorOTHER
Regend Therapeutics
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with COPD, BE or PF according to the guideline; * Clinically stable for more than 4 weeks; * Tolerant to fiberoptic bronchoscopy test; * Written informed consent signed.

Exclusion criteria

* Pregnant or lactating women; * Patients positive for syphilis, HIV; * Patients with malignant tumor; * Patients with serious significant pulmonary infection and need anti-infection treatment; * Patients with serious heart disease(NYHA class Ⅲ-Ⅳ); * Patients with a history of abusing alcohol and illicit drug; * Patients participated in other clinical trials in the past 3 months; * Patients assessed as inappropriate to participate in this clinical trial by investigators.

Design outcomes

Primary

MeasureTime frameDescription
Forced expiratory volume in one second (FEV1)1-6 monthsOne of the indicators in pulmonary function test, a marker to assess airway obstruction
Diffusion capacity of CO (DLCO)1-6 monthsOne of the indicators in pulmonary function test, the extent to which oxygen passes from the air sacs of the lungs into the blood

Secondary

MeasureTime frameDescription
Maximum voluntary ventilation (MVV)1-6 monthsOne of the indicators in pulmonary function test, measuring the maximum amount of air that can be inhaled and exhaled within one minute
Forced vital capacity (FVC)1-6 monthsOne of the indicators in pulmonary function test, indicating the maximum amount of air a person can expel from the lungs after a maximum inhalation
6-minute-walk test (6MWT)1-6 monthsAn indicator to evaluate the exercise function of patients with moderate or severe pulmonary heart diseases
The ratio of forced expiratory volume in the first one second to the forced vital capacity (FEV1/FVC)1-6 monthsOne of the indicators in pulmonary function test, representing the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration to the full vital capacity
St. George's respiratory questionnaire (SGRQ) scale1-6 monthsA questionnaire to assess life quality affected by the respiratory problems
Imaging of lung by high resolution computed tomography (HR-CT)1-6 monthsHR-CT images of lung will be analyzed to indicate the pulmonary structure.
Modified medical research council (MMRC) chronic dyspnea scale1-6 monthsAn indicator to evaluate the level of dyspnea
Maximum mid-expiratory flow (MMF)1-6 monthsOne of the indicators in pulmonary function test, standing for maximal (mid-)expiratory flow and is the peak of expiratory flow as taken from the flow-volume curve and measured in liters per second

Countries

China

Contacts

Primary ContactWei Zuo, Ph. D.
zuow@regend.cn086-400-882-1090
Backup ContactJianan Huang, M. D.
huang_jian_an@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026